ALIBABA-CLOUD
9.1.2023 07:58:17 CET | Business Wire | Press release
Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group (NYSE: BABA; HKEX: 9988), today unveiled at the Alibaba Cloud Singapore Summit 2023 its first international product innovation center and partner management center, to further enhance customer services and better facilitate customers’ digitalization journey.
The new Product Innovation Center will help facilitate future roadmaps for developing more market-specific solutions, and will oversee the management of product upgrades based on ongoing global customer demands. To better serve local customers’ needs, the Partner Management Center will be launched to delve into local collaborations to deepen the sharing of leading technologies and domain expertise amongst partners.
These new initiatives will not only create more job opportunities for local talents in Singapore but will also enhance more local collaborations through the creation of a new Innovation Accelerator Program to support businesses to expand as the global digital economy continues to grow.
The Innovation Accelerator Program aims to bring together industry leaders and experts to help develop more innovative and resilient businesses in Singapore through sharing of practical skills and ideas, and providing ease of access to the latest cloud technologies. Each eligible company under the program will also receive complimentary training and technical support from Alibaba Cloud and industry experts.
By supporting businesses with their digital transformation and innovation journey through upskilling, retraining, and technical upgrading, the program also provides them with an opportunity to plug into the dynamic global ecosystem of Alibaba Cloud, which is designed to further empower businesses to explore and realize their growth ambitions not only locally but also internationally.
“Today we are in a very early stage of digitalization,” said Dr. Wang Jian, Member of Chinese Engineering Academy and founder of Alibaba Cloud. “In the next five to ten years, the economy is going to be driven and measured by computing consumption. Digital economy is the economy of computing, and cloud computing will play the same role in the era of digitalization as electricity played in the era of electrification. The cloud is becoming a methodology not just for cloud computing, but a methodology for most people doing their work.”
In a bid to complement sustainable business strategies, Alibaba Cloud will also be working with partners to help 10,000 global companies to accelerate their sustainability journey over the next three years. Businesses in Singapore will be offered a pilot program of Energy Expert to help reduce their carbon footprints. A proprietary software-as-a-service sustainability platform launched by Alibaba Cloud in June last year, Energy Expert helps measure, analyze, and manage the carbon emissions of business activities and products while providing actionable insights and energy-saving recommendations to companies in helping them achieve their carbon emission goals.
“With the setup of our first International Product Innovation Center and Partner Management Center in Singapore, our global headquarters for Alibaba Cloud, we are committed to continuously supporting global businesses in their digital transformation journey. The new initiatives and the strengthening of our talented workforce further illustrate our support for global customers with ambitions to expand and upgrade their innovation capabilities, while delivering on their sustainability goals,” said Selina Yuan, Vice President of Alibaba Group and President of Alibaba Cloud Intelligence International Business Unit.
Attaining the highest tier of CSA cybersecurity certification
A critical part of Alibaba Cloud’s continuous efforts is to bring better services and offerings to businesses and these include enhanced cybersecurity and protection for customers. Alibaba Cloud has recently attained the Cyber Trust (Advocate) mark certification. The Cyber Trust mark, developed by the Cyber Security Agency of Singapore (CSA), is targeted at larger or more digitalized organizations, and helps organizations to communicate their investment in cybersecurity as a competitive edge and to build trust with their customers.
The Cyber Trust (Advocate) mark is the highest tier of the certification. It affirms Alibaba Cloud’s dedication to offer trusted services for businesses to manage and protect their cloud infrastructure.
Supporting Customers’ Growth with Technology for Innovation
Gadget MIX is a Singapore-based retailer with more than 20 outlets across the country and a robust e-commerce presence that focuses on high-tech digital products. Alibaba Cloud has helped Gadget MIX digitally transform its retail strategy through providing innovative cloud solutions. Partnering with Alibaba Cloud has allowed Gadget MIX to improve internal communications, streamline business operations, and seamlessly migrate to the cloud to speed up its business transformation.
“The solutions provided by Alibaba Cloud have helped to lower our total cost of ownership and streamline business operations, thus speeding up our business transformation efforts. In particular, the deployment of DingTalk has helped us to improve workflow management and team collaborations as well as our business and internal communications. Through our digital transformation efforts together with Alibaba Cloud, we have succeeded in creating more value for our retail customers and look forward to future collaborations around digital transformation,” said Ray Yue, CEO of Gadget MIX.
Leveraging Alibaba Cloud’s game accelerator solution and security products like Game Shield and Anti-DDos, Project Twelve (P12), a web3 gaming platform headquartered in Singapore, is now able to focus on scalable game deployment while providing a secure environment for their users by lowering the risks of cyberattacks. P12 also utilizes Alibaba Cloud’s cloud native database, PolarDB, to reduce maintenance time and improve uptime reliability, thus creating a smooth gamer experience.
“With added assurance for a secure gaming experience within P12 platform, we can focus our efforts on elevating the platform with quality games and sustainable economy in the fast-moving and dynamic web3 gaming industry. Alibaba Cloud’s solutions have helped us to provide our users with smoother gaming experiences and scale accordingly to peak demands with high availability and low latency,” said Boyang, founder of Project Twelve.
With Singapore as a vibrant logistics hub and it being a key pillar of the Singapore economy, Alibaba Cloud has also been working with many logistics players to deepen their digital transformation efforts. This includes JUSTI Pte. Ltd. (JUSTI), a homegrown investment holding company whose main investment portfolios includes a last mile delivery operation. Alibaba Cloud’s solutions have enabled them to digitalize and streamline its logistic networks.
“Alibaba Cloud’s AI-driven EasyDispatch solution with an embedded vehicle routing problem (VRP) capability improves our field dispatch capabilities and efficiency in real time. By utilizing Alibaba Cloud’s technologies, we can have better visibility and control over each step of our delivery chains, such as parcel status tracking, real-time AI route designing and task scheduling. They have greatly reduced our manpower cost and increase customers’ satisfaction,” said Li ChaoMing, Managing Director of JUSTI.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com) is the digital technology and intelligence backbone of Alibaba Group. It offers a complete suite of cloud services to customers worldwide, including elastic computing, database, storage, network virtualization services, large-scale computing, security, management and application services, big data analytics, a machine learning platform and IoT services. Alibaba maintained its position as the third leading public cloud IaaS service provider globally since 2018, according to IDC. Alibaba is the world’s third leading and Asia Pacific’s leading IaaS provider by revenue in U.S. dollars since 2018, according to Gartner.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230108005098/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom